Guotai Asset Management sees China innovative drug rally as event-driven rebound after pullback
XBI•Guotai flags rebound in China innovative drugs and CXO complex
Guotai Asset Management flagged a sharp rebound in China’s innovative-drug and CXO complex, with tracked indices up more than 4% at the close.
- WCLC clinical updates drove sentiment, led by stronger interim overall-survival results for a PD-1/VEGF bispecific in first-line NSCLC.
- Positive interim Phase III readouts for a B7H3 ADC in second-line SCLC reinforced “ADC plus lung cancer” positioning, supporting licensing expectations.
- The firm expects CXO demand to hold up as peptides, ADCs, and complex small molecules move into commercial stockpiling and supply.
- Guotai sees higher near-term earnings visibility into third-quarter results, while warning macro volatility could disrupt the trade.
Related News
Corbus says Phase 1b CANYON-1 trial shows CRB-913 delivers 5% mean weight loss at 12 weeks in obesity study
CRBP•
Definium Therapeutics says Phase 3 Panorama trial meets primary endpoint for DT120 ODT in generalized anxiety disorder
DFTX•
